HomeALCLS • EPA
add
Cellectis SA
Nakaraang pagsara
€1.74
Sakop ng araw
€1.68 - €1.74
Sakop ng taon
€1.41 - €3.03
Market cap
121.92M EUR
Average na Volume
66.82K
P/E ratio
-
Dividend yield
-
Primary exchange
EPA
Mga balita tungkol sa merkado
Mga Financial
Income Statement
Kita
Net na kita
| (USD) | Set 2024info | Y/Y na pagbabago |
|---|---|---|
Kita | 18.05M | 997.99% |
Gastos sa pagpapatakbo | 28.82M | 29.16% |
Net na kita | -23.06M | -31.88% |
Net profit margin | -127.73 | 87.99% |
Kita sa bawat share | -0.22 | 40.54% |
EBITDA | -8.00M | 55.99% |
Aktuwal na % ng binabayarang buwis | 0.26% | — |
Balance Sheet
Kabuuang asset
Kabuuang sagutin
| (USD) | Set 2024info | Y/Y na pagbabago |
|---|---|---|
Cash at mga panandaliang investment | 159.09M | 136.18% |
Kabuuang asset | 395.88M | 88.78% |
Kabuuang sagutin | 266.45M | 99.47% |
Kabuuang equity | 129.42M | — |
Natitirang share | 100.09M | — |
Presyo para makapag-book | 1.35 | — |
Return on assets | -6.71% | — |
Return on capital | -11.77% | — |
Cash Flow
Net change in cash
| (USD) | Set 2024info | Y/Y na pagbabago |
|---|---|---|
Net na kita | -23.06M | -31.88% |
Cash mula sa mga operasyon | -5.83M | 65.90% |
Cash mula sa pag-invest | 22.33M | 7,544.33% |
Cash mula sa financing | -4.22M | -349.88% |
Net change in cash | 10.05M | 159.00% |
Malayang cash flow | 23.63M | 366.56% |
Tungkol
Cellectis is a French biopharmaceutical company. It develops genome-edited chimeric antigen receptor T-cell technologies for cancer immunotherapy. It has offices in Paris, New York City, and Raleigh, North Carolina. Wikipedia
Itinatag
1999
Website
Mga Empleyado
219
